Tetraphase Pharmaceuticals, Inc.
If you purchased Tetraphase Pharmaceuticals, Inc. securities and would like to join the action, please click "Join This Action" below.
TETRAPHASE MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF TETRAPHASE PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – TTPH
March 16, 2020.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) to AcelRx Pharmaceuticals, Inc. for 0.6303 shares of AcelRx for each share of Tetraphase is fair to Tetraphase shareholders. On behalf of Tetraphase shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
The Tetraphase merger investigation concerns whether Tetraphase and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible consideration for Tetraphase shareholders; (2) determine whether AcelRx is underpaying for Tetraphase; and (3) disclose all material information necessary for Tetraphase shareholders to adequately assess and value the merger consideration.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.